|
CN103340852A
|
|
Pharmaceutical composition containing ezetimibe and atorvastatin
|
|
CN103315963A
|
|
Stable lamivudine granule
|
|
CN103301078A
|
|
Lyophilized preparation of D-sodium lansoprazole, and preparation method thereof
|
|
CN103301467A
|
|
Stable taste-masking ambroxol hydrochloride compound and preparation method thereof
|
|
CN103301082A
|
|
Oral tablet with tofisopam as active ingredient, and application of oral tablet
|
|
CN103301063A
|
|
S (+) -flurbiprofen axetil emulsion for injection
|
|
CN103301071A
|
|
Stable entecavir sugarless granules and preparation method thereof
|
|
CN103284985A
|
|
Stable (S)-alpha-methyl-4-(2-methylpropyl) phenylacetic acid medicine composition
|
|
CN103251564A
|
|
Azacitidine for injection and preparation method thereof
|
|
CN103070833A
|
|
Freeze-dried powder injection of propionyl-L-carnitine hydrochloride and preparation method of freeze-dried powder injection
|
|
CN103070865A
|
|
Oral solid preparation taking prucalopride succinate as active ingredient and application of oral solid preparation
|
|
CN103054860A
|
|
Solid preparation of benzenesulfonic acid prasugrel
|
|
CN103054857A
|
|
Solid preparation taking ramatroban as active ingredient
|
|
CN103271899A
|
|
Application of Retigabine dihydrochloride crushing granularity in preparation
|
|
CN103054823A
|
|
Solid preparation taking distigmine bromide as active ingredient
|
|
CN103054882A
|
|
Solid preparation taking benexate as active ingredient
|
|
CN103054861A
|
|
Compound solid preparation containing tranexamic acid
|
|
CN103054865A
|
|
Stable niacin simvastatin sustained-release tablet and preparation method thereof
|
|
CN103054896A
|
|
Compound dry suspension preparation containing omeprazole and sodium bicarbonate
|
|
CN103070869A
|
|
Medicine composition for treating mental disorder
|
